טוען...
The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
The β(3)‐adrenoceptor agonist mirabegron is approved for use for overactive bladder and has been purported to be useful in the treatment of obesity‐related metabolic diseases in humans, including those involving disturbances of glucose homeostasis. We investigated the effect of mirabegron on glucose...
שמור ב:
| הוצא לאור ב: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7437350/ https://ncbi.nlm.nih.gov/pubmed/32813332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.643 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|